Company Filing History:
4 out of 240 
2 out of 897 
Years Active: 1999-2021
Title: The Innovative Contributions of Laszlo Hackler
Introduction
Laszlo Hackler is a notable inventor based in Metairie, Louisiana, recognized for his significant contributions to the field of pain management through innovative peptide analogs. With a total of 4 patents, Hackler has made strides in developing compounds that offer therapeutic benefits with reduced side effects.
Latest Patents
Hackler's latest patents focus on mu opioid receptor agonist analogs of endomorphins. These inventions relate to cyclic peptide agonists that bind to the mu (morphine) opioid receptor, providing potential treatments for both acute and chronic pain. The embodiments of these inventions include cyclic analogs of endomorphin that exhibit decreased tolerance compared to morphine, as well as increased solubility relative to similar tetrapeptide analogs. Furthermore, these peptide analogs maintain favorable or improved therapeutic ratios of analgesia to side effects. Another aspect of his recent work involves cyclic pentapeptide and hexapeptide analogs of endomorphin, which feature a carboxy-terminal extension with an amidated hydrophilic amino acid and a substitution in amino acid position 2. These advancements continue to highlight Hackler's commitment to improving pain management therapies.
Career Highlights
Throughout his career, Hackler has worked with esteemed organizations, including the Administrators of the Tulane Educational Fund and the United States Government as represented by the Department of Veterans Affairs. His work in these institutions has allowed him to contribute to significant research and development in the field of pharmaceuticals.
Collaborations
Hackler has collaborated with notable colleagues such as James E. Zadina and Abba J. Kastin. These partnerships have further enriched his research and innovation efforts, leading to advancements in pain management solutions.
Conclusion
Laszlo Hackler's innovative work in developing mu opioid receptor agonist analogs has the potential to transform pain management therapies. His contributions reflect a dedication to improving patient outcomes while minimizing side effects.